MOTS-c: Research Overview

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino acid peptide encoded not in the nuclear genome but within the 12S ribosomal RNA gene of mitochondrial DNA. Discovered in 2015, it belongs to a growing class of peptides called mitochondrial-derived peptides (MDPs). MOTS-c is produced in mitochondria, translocated to the cytoplasm and nucleus, and has been studied for its role in metabolic regulation, insulin sensitivity, and the molecular response to exercise. The evidence base is predominantly preclinical; published human data is limited.

What Is MOTS-c?

MOTS-c has a molecular weight of approximately 2,173 Da and an amino acid sequence of MRWQEMGYIFYPRKLR. Its origin in mitochondrial DNA is biologically unusual: virtually all signaling peptides are encoded by the nuclear genome, but MOTS-c is translated from an open reading frame within the mitochondrial 12S rRNA gene. This suggests it may function as a retrograde signal from mitochondria to the nucleus, integrating cellular energy status with gene expression.

In plasma, MOTS-c levels have been reported to respond to exercise, rising approximately 50% during and after physical activity in young healthy men before returning to baseline. Circulating MOTS-c levels are also reported to decline with aging, with some population data noting lower levels in elderly compared to young adults, though the clinical significance of these observations requires further study.

Mechanism of Action

The primary characterized mechanism of MOTS-c involves the folate cycle and AMPK (AMP-activated protein kinase) pathway. In skeletal muscle, MOTS-c inhibits the folate cycle, which leads to accumulation of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), an endogenous AMPK activator. AMPK activation in turn upregulates glucose uptake, fatty acid oxidation, and mitochondrial biogenesis while inhibiting anabolic processes. This pathway overlaps with metabolic effects associated with exercise and caloric restriction.

MOTS-c also translocates to the nucleus under conditions of metabolic stress, where it has been shown to bind directly to gene promoters and modulate the expression of stress-adaptive and metabolic genes, including those in the Nrf2 antioxidant response pathway. This nuclear activity is distinct from the cytoplasmic AMPK pathway and suggests MOTS-c may function as a transcriptional co-regulator.

What the Research Shows

Landmark Discovery Study (Lee et al., 2015)

The foundational study by Lee et al. published in Cell Metabolism in 2015 (PMID 25738459) identified MOTS-c as a mitochondrially encoded peptide and characterized its metabolic effects. In mouse models, systemic MOTS-c administration prevented high-fat diet-induced insulin resistance and obesity, improved glucose tolerance, and enhanced glucose uptake in skeletal muscle. MOTS-c also prevented age-dependent insulin resistance in aged mice. These effects were attributed to AMPK activation downstream of the folate-AICAR pathway.

Exercise and Muscle Homeostasis

A 2021 study in Nature Communications (Reynolds et al., PMID 33504779) demonstrated that MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline. In aged mice, MOTS-c injection significantly improved running capacity and skeletal muscle function, with effects exceeding those seen in younger mice receiving the same treatment. The peptide was described as an exercise-mimetic or “exerkine” — a molecule that reproduces aspects of exercise-induced adaptation. These findings remain preclinical.

Limitations of the Current Evidence Base

The published literature on MOTS-c consists almost entirely of in vitro cell culture and rodent studies. As of early 2026, no randomized controlled trials in humans have evaluated MOTS-c as an administered compound. Population studies showing associations between circulating MOTS-c levels and metabolic phenotypes are observational and cannot establish causation. The translation of murine findings to human physiology is not established. Researchers and reviewers should weigh this evidence accordingly.

Pharmacokinetics

Formal human pharmacokinetic studies of exogenously administered MOTS-c have not been published as of early 2026. Endogenous circulating MOTS-c has a reported half-life of approximately 1–2 hours based on exercise response kinetics, with exercise-induced peaks returning to baseline within approximately 4 hours. Its molecular weight is 2,173 Da. Subcutaneous and intraperitoneal routes have been used in murine studies. Without human PK data, extrapolation of these values to exogenous dosing in humans carries substantial uncertainty.

Common Research Dose Ranges

DISCLAIMER: The following dose ranges are drawn from preclinical (animal) research literature and are provided for informational and research reference purposes only. No human clinical dose has been established. These values are not medical advice, prescribing guidance, or a recommendation to use this compound.

Published preclinical studies have not consistently reported absolute milligram doses in a form directly comparable to human research compound use. The landmark Lee et al. (2015) study used intraperitoneal injection in mice; the Reynolds et al. (2021) study used subcutaneous injection. Both the dose and the route in the murine literature differ substantially from how MOTS-c is typically supplied and used in research settings. No phase 1 human dosing data exist in the peer-reviewed literature.

Storage

Lyophilized MOTS-c should be stored at −20 °C in a desiccated environment. Following reconstitution, solutions should be kept at 2–8 °C and used within 14 days per standard research peptide storage guidance.

What MOTS-c Is NOT

MOTS-c is not a growth hormone secretagogue, GLP-1 receptor agonist, or anabolic peptide. It is mechanistically distinct from humanin (another mitochondrial-derived peptide) despite both originating from the mitochondrial genome. MOTS-c is not FDA-approved for any use, and no clinical trials in humans have been registered or completed as of early 2026. It is not an exercise substitute and the “exerkine” designation reflects a mechanistic parallel, not a therapeutic equivalence.

References

See citations below.